SARS-CoV-2 Infection Clinical Trial
— HYGIEIAOfficial title:
Hypothesizing the Genesis of Infectious Diseases and Epidemics Through an Integrated Systems Biology Approach
In this study, the investigators aim to collect phenotypical and extensive unbiased multimodal biological data, at two different time points, and to integrate them using a systems biology approach. The present project aims at generating a systems biology network that can recapitulate the complexity of processes underlying differential SARS-CoV-2 phenotypic responses through exploitation of clinical -omics data. Identifying key determinants and mechanisms of biological variability responsible for phenotypic differences will lead to a better management of patients through the application of precision medicine.
Status | Recruiting |
Enrollment | 275 |
Est. completion date | September 30, 2024 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years or over - Patient or legal representative have provided informed consent - Cases: Reverse-transcriptase polymerase chain reaction (RT-PCR) confirmed symptomatic SARS-CoV-2 infection. - Controls : (1) Patient presenting with hypoxemic respiratory failure diagnosed by the treating physician as being from infectious origin; (2) SARS-CoV-2 infection excluded by RT-PCR and deemed non-probable by the treating physician. - Healthy controls : Patients presenting without acute respiratory failure (ie. SpO2 >93%); (2) no RT-PCR or antigen rapid test proven SARS-CoV-2 infection within the last 6 months; (3) no active respiratory tract infection. Exclusion Criteria: - For all: (1) <18 years old ; (2)unwilling to provide informed consent; (3) pregnancy at the time of inclusion - For cases: Asymptomatic infection - For controls: COVID-19 diagnosed by RT-PCR or suspect according to the treating physician at the time of inclusion, - For health controls: Acute or chronic respiratory failure. |
Country | Name | City | State |
---|---|---|---|
Belgium | Cliniques Universitaires Saint-Luc | Brussels |
Lead Sponsor | Collaborator |
---|---|
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change on the 11 points World Health Organization (WHO) clinical progression scale | Evaluation of disease state on the 11 points WHO Clinical Progression Scale. The minimum value is 0 and corresponds to an uninfected status and the maximum value is 10 in case of death. So a higher score means a worse outcome. | At inclusion (for hospitalized patients daily evaluation untill discharge) and at the end of study visit between 8 and 12 weeks later |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04593641 -
This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
|
Phase 1 | |
Recruiting |
NCT05200754 -
Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High-Risk Patients With COVID-19
|
Phase 2 | |
Completed |
NCT04583995 -
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
|
Phase 3 | |
Recruiting |
NCT06255860 -
SARS-COV-2 Reinfection and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk: Matched Case-control Study
|
||
Recruiting |
NCT04516811 -
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
|
Phase 3 | |
Recruiting |
NCT05012826 -
Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID
|
N/A | |
Completed |
NCT05007236 -
Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.
|
Phase 2 | |
Recruiting |
NCT06026514 -
Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults
|
Phase 1 | |
Completed |
NCT05523739 -
Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients
|
Phase 1 | |
Suspended |
NCT04738136 -
Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia
|
Phase 2 | |
Recruiting |
NCT04584658 -
Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)
|
||
Recruiting |
NCT04547114 -
Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects
|
||
Completed |
NCT05119348 -
Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
|
N/A | |
Completed |
NCT05096962 -
COVID-19: SARS-CoV-2-CZ-PREVAL-II Study
|
||
Recruiting |
NCT04534400 -
Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure
|
||
Completed |
NCT04527354 -
Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia
|
Phase 2 | |
Completed |
NCT04583982 -
ImmuneSense™ COVID-19 Study
|
||
Completed |
NCT05077176 -
Phase 3 Booster Vaccination Against COVID-19
|
Phase 3 | |
Completed |
NCT05584189 -
COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability
|
N/A |